Antibodies to biotinylated red blood cells in adults and infants: improved detection, partial characterization, and dependence on red blood cell‐biotin dose

BACKGROUND Biotin‐labeled red blood cells (BioRBCs) are used for in vivo kinetic studies. Because BioRBC dosing occasionally induces antibodies, a sensitive and specific anti‐BioRBC detection assay is needed. STUDY DESIGN AND METHODS Aims were to 1) develop a gel card assay to evaluate existing, nat...

Full description

Saved in:
Bibliographic Details
Published inTransfusion (Philadelphia, Pa.) Vol. 57; no. 6; pp. 1488 - 1496
Main Authors Schmidt, Robert L., Mock, Donald M., Franco, Robert S., Cohen, Robert M., North, Anne K., Cancelas, José A., Geisen, Christof, Strauss, Ronald G., Vlaar, Alexander P., Nalbant, Demet, Widness, John A.
Format Journal Article
LanguageEnglish
Published United States 01.06.2017
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:BACKGROUND Biotin‐labeled red blood cells (BioRBCs) are used for in vivo kinetic studies. Because BioRBC dosing occasionally induces antibodies, a sensitive and specific anti‐BioRBC detection assay is needed. STUDY DESIGN AND METHODS Aims were to 1) develop a gel card assay to evaluate existing, naturally occurring and BioRBC‐induced plasma antibodies, 2) compare gel card and tube agglutination detection results, and 3) test for a relationship of antibody induction and BioRBC dose. Reagent BioRBCs were prepared using sulfo‐NHS biotin ranging from densities 18 (BioRBC‐18) to 1458 (BioRBC‐1458) µg/mL RBCs. RESULTS Among BioRBC‐exposed subjects, gel card and tube agglutination results were concordant in 21 of 22 adults and all 19 infant plasma samples. Gel card antibody detection sensitivity was more than 10‐fold greater than tube agglutination. Twelve to 16 weeks after BioRBC exposure, induced anti‐antibodies were detected by gel card in three of 26 adults (12%) at reagent densities BioRBC‐256 or less, but in none of 41 infants. Importantly, induced anti‐BioRBC antibodies were associated with higher BioRBC dose (p = 0.008); no antibodies were detected in 18 subjects who received BioRBC doses less than or equal to BioRBC‐18. For noninduced BioRBC antibodies, six of 1125 naïve adults (0.3%) and none of 46 naïve infants demonstrated existing anti‐BioRBC antibodies using reagent BioRBC‐140 or ‐162. Existing anti‐BioRBCs were all neutralized by biotin compounds, while induced antibodies were not. CONCLUSIONS The gel card assay is more sensitive than the tube agglutination assay. We recommend reagent BioRBC‐256 for identifying anti‐BioRBCs. Use of a low total RBC biotin label dose (≤ BioRBC‐18) may minimize antibody induction.
Bibliography:This work was supported by NIH Program Project Grant P01 HL046925. It also received support from the National Center for Advancing Translational Sciences, and the National Institutes of Health (NIH) (Grant 2 UL1 TR000442‐06 and S10 OD016199‐01A1 grant UL1TR000039), as well as VA Merit Award (1 I01 CX000121), and NIH Clinical and Translational Science Award (CTSA) program (1UL1 TR001425). The content is solely the responsibility of the authors and does not represent the official views of the NIH.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0041-1132
1537-2995
1537-2995
DOI:10.1111/trf.14075